- Home
- AENT vs ACIU Comparison
AENT vs ACIU Comparison
Compare AENT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- ACIU
- Stock Information
- Founded
- AENT 1990
- ACIU 2003
- Country
- AENT United States
- ACIU Switzerland
- Employees
- AENT N/A
- ACIU N/A
- Industry
- AENT Durable Goods
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- ACIU Health Care
- Exchange
- AENT Nasdaq
- ACIU Nasdaq
- Market Cap
- AENT 161.5M
- ACIU 189.1M
- IPO Year
- AENT N/A
- ACIU 2016
- Fundamental
- Price
- AENT $4.97
- ACIU $2.18
- Analyst Decision
- AENT Strong Buy
- ACIU Strong Buy
- Analyst Count
- AENT 1
- ACIU 1
- Target Price
- AENT $10.00
- ACIU $12.00
- AVG Volume (30 Days)
- AENT 42.0K
- ACIU 148.9K
- Earning Date
- AENT 09-18-2025
- ACIU 08-12-2025
- Dividend Yield
- AENT N/A
- ACIU N/A
- EPS Growth
- AENT N/A
- ACIU N/A
- EPS
- AENT 0.23
- ACIU N/A
- Revenue
- AENT $1,072,641,000.00
- ACIU $32,014,254.00
- Revenue This Year
- AENT N/A
- ACIU N/A
- Revenue Next Year
- AENT $0.73
- ACIU $533.21
- P/E Ratio
- AENT $21.40
- ACIU N/A
- Revenue Growth
- AENT N/A
- ACIU 91.20
- 52 Week Low
- AENT $1.10
- ACIU $1.43
- 52 Week High
- AENT $11.57
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- AENT 48.82
- ACIU 52.41
- Support Level
- AENT $5.57
- ACIU $2.02
- Resistance Level
- AENT $5.70
- ACIU $2.52
- Average True Range (ATR)
- AENT 0.59
- ACIU 0.15
- MACD
- AENT -0.15
- ACIU 0.01
- Stochastic Oscillator
- AENT 11.56
- ACIU 34.62
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.